Potassium acetate

Identification

Name
Potassium acetate
Accession Number
DB14498  (DBSALT001427)
Type
Small Molecule
Groups
Approved, Investigational
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Active Moieties
NameKindUNIICASInChI Key
Potassium cationionic295O53K15224203-36-9NPYPAHLBTDXSSS-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Potassium AcetateLiquid392 mgIntravenousSandoz Canada Incorporated1988-12-312016-10-24Canada
Potassium AcetateInjection, solution, concentrate196.3 mg/1mLIntravenousHospira, Inc.2013-12-23Not applicableUs
Potassium AcetateInjection, solution, concentrate3.93 g/20mLIntravenousHospira, Inc.2005-07-07Not applicableUs
Potassium Acetate Inj 2meq/mlSolution2 meqIntravenousAbbott1984-12-312008-06-06Canada
Potassium Acetate Inj 392mg/ml USPLiquid392 mgIntravenousLyphomed, Division Of Fujisawa Canada Inc.1984-12-311996-09-10Canada
Potassium Acetate InjectionSolution392 mgIntravenousFresenius Kabi1984-12-31Not applicableCanada
Potassium Acetate Injection USPLiquid39.2 %IntravenousOmega Laboratories Ltd2016-07-18Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Potassium AcetateInjection, solution, concentrate3.93 g/20mLIntravenousExela Pharma Sciences, Llc.2016-01-07Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AminosynPotassium acetate (128 mg/100mL) + Glycine (448 mg/100mL) + Histidine (105 mg/100mL) + L-Alanine (448 mg/100mL) + L-Arginine (343 mg/100mL) + L-Isoleucine (252 mg/100mL) + L-Leucine (329 mg/100mL) + L-Lysine acetate (252 mg/100mL) + L-Phenylalanine (154 mg/100mL) + L-Proline (300 mg/100mL) + L-Threonine (182 mg/100mL) + L-Tryptophan (56 mg/100mL) + L-Tyrosine (31 mg/100mL) + L-Valine (280 mg/100mL) + Magnesium acetate (21 mg/100mL) + Methionine (140 mg/100mL) + Phosphoric acid (40 mg/100mL) + Serine (147 mg/100mL) + Sodium Chloride (234 mg/100mL)Injection, solutionIntravenousHospira, Inc.2011-03-23Not applicableUs
Aminosyn 3.5% MPotassium acetate (128 mg) + Glycine (448 mg) + Histidine (105 mg) + L-Alanine (448 mg) + L-Arginine (343 mg) + L-Isoleucine (252 mg) + L-Leucine (329 mg) + L-Lysine acetate (252 mg) + L-Phenylalanine (154 mg) + L-Proline (300 mg) + L-Threonine (182 mg) + L-Tryptophan (56 mg) + L-Tyrosine (31 mg) + L-Valine (280 mg) + Magnesium acetate (21 mg) + Methionine (140 mg) + Serine (147 mg) + Sodium Chloride (234 mg)LiquidIntravenousAbbott1980-12-311999-08-09Canada
Hyperlyte (multi-electrolyte Concentrate)Potassium acetate (690 mg) + Calcium Acetate (440 mg) + Sodium gluconate (1.09 g) + Magnesium acetate (860 mg) + Potassium Chloride (2.46 g) + Sodium acetate (2.72 g)LiquidIntravenousB. Braun Medical Inc.1998-09-04Not applicableCanada
Hyperlyte CR Multi-electrolyte ConcentratePotassium acetate (1.96 g) + Calcium Chloride (370 mg) + Magnesium chloride (510 mg) + Sodium Chloride (1.17 g) + Sodium acetate (680 mg)LiquidIntravenousB. Braun Medical Inc.1998-09-03Not applicableCanada
LypholytePotassium acetate (690 mg) + Calcium Acetate (440 mg) + Sodium gluconate (1.1 g) + Magnesium acetate (860 mg) + Potassium Chloride (2.5 g) + Sodium acetate (2.7 g)SolutionIntravenousPartners Health Care, Inc.1996-08-142008-01-10Canada
Lypholyte Multi-electrolyte Conc InjPotassium acetate (34.5 mg) + Calcium Acetate (22 mg) + Sodium gluconate (55 mg) + Magnesium acetate (43 mg) + Potassium Chloride (125 mg) + Sodium acetate (135 mg)LiquidIntravenousLyphomed, Division Of Fujisawa Canada Inc.1991-12-311996-09-10Canada
Normosol-M & 5% DextrosePotassium acetate (0.128 g) + Dextrose, unspecified form (5 g) + Magnesium acetate (0.021 g) + Sodium Chloride (0.234 g)SolutionIntravenousIcu Medical Canada Inc1965-12-31Not applicableCanada
Normosol-M and DextrosePotassium acetate (128 mg/100mL) + D-glucose monohydrate (5 g/100mL) + Magnesium acetate (21 mg/100mL) + Sodium Chloride (234 mg/100mL)Injection, solutionIntravenousHospira, Inc.1975-08-131975-08-14Us
Plasma-lyte 56 5% Dextrose InjPotassium acetate (128 mg) + Dextrose, unspecified form (5 g) + Magnesium acetate (32 mg) + Sodium Chloride (234 mg)LiquidIntravenousBaxter Laboratories1990-12-312014-04-17Canada
Plasma-lyte 56 and DextrosePotassium acetate (128 mg/100mL) + D-glucose monohydrate (5 g/100mL) + Magnesium acetate tetrahydrate (32 mg/100mL) + Sodium Chloride (234 mg/100mL)Injection, solutionIntravenousBaxter Laboratories1979-02-012016-10-31Us
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Hyperlyte CRPotassium acetate (1.96 g/20mL) + Calcium chloride dihydrate (0.37 g/20mL) + Magnesium chloride hexahydrate (0.51 g/20mL) + Sodium Chloride (1.17 g/20mL) + Sodium acetate trihydrate (0.68 g/20mL)Injection, solution, concentrateIntravenousB. Braun Medical Inc.2012-04-12Not applicableUs
NutrilytePotassium acetate (34.5 mg/1mL) + Calcium Acetate (22 mg/1mL) + Sodium gluconate (55 mg/1mL) + Magnesium acetate (43 mg/1mL) + Potassium Chloride (125 mg/1mL) + Sodium acetate trihydrate (135 mg/1mL)Injection, solution, concentrateIntravenousAmerican Regent1990-09-302013-05-08Us
Nutrilyte IIPotassium acetate (98 mg/1mL) + Calcium chloride dihydrate (16.55 mg/1mL) + Magnesium chloride hexahydrate (25.5 mg/1mL) + Sodium Chloride (74.5 mg/1mL) + Sodium acetate trihydrate (64.6 mg/1mL)Injection, solution, concentrateIntravenousAmerican Regent1990-10-012014-01-01Us
Nutrilyte IIPotassium acetate (98 mg/1mL) + Calcium chloride dihydrate (16.55 mg/1mL) + Magnesium chloride hexahydrate (25.5 mg/1mL) + Sodium Chloride (74.5 mg/1mL) + Sodium acetate trihydrate (64.6 mg/1mL)Injection, solution, concentrateIntravenousAmerican Regent1990-10-012014-01-01Us
Plasma-lyte 56Potassium acetate (1.28 mg/1mL) + Magnesium acetate tetrahydrate (.23 mg/1mL) + Sodium Chloride (2.34 mg/1mL)InjectionIntravenousBaxter Laboratories2006-09-19Not applicableUs
Potassium AcetatePotassium acetate (392 mg/1mL)Injection, solution, concentrateIntravenousAmerican Regent1990-09-302014-07-01Us
Potassium AcetatePotassium acetate (196 mg/1mL)Injection, solutionIntravenousAmerican Regent1990-09-302012-11-29Us
Categories
UNII
M911911U02
CAS number
127-08-2
Weight
Average: 98.1423
Monoisotopic: 97.977011201
Chemical Formula
C2H3KO2
InChI Key
SCVFZCLFOSHCOH-UHFFFAOYSA-M
InChI
InChI=1S/C2H4O2.K/c1-2(3)4;/h1H3,(H,3,4);/q;+1/p-1
IUPAC Name
potassium acetate
SMILES
[K+].CC([O-])=O

Pharmacology

Indication

Potassium is used to regulate hypokalemia as a primary condition or secondary to other medical conditions.

Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action

Potassium is the major cation (positive ion) inside animal cells, while sodium is the major cation outside animal cells. The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential. The balance between potassium and sodium is maintained by ion pumps in the cell membrane. The cell membrane potential created by potassium and sodium ions allows the cell generate an action potential—a "spike" of electrical discharge. The ability of cells to produce electrical discharge is critical for body functions such as neurotransmission, muscle contraction, and heart function. Potassium is also an essential mineral needed to regulate water balance, blood pressure and levels of acidity.

TargetActionsOrganism
USodium/potassium-transporting ATPase subunit alpha-1Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Mostly urine but also skin and feces.

Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AcebutololThe risk or severity of hyperkalemia can be increased when Potassium acetate is combined with Acebutolol.
AcetaminophenAcetaminophen may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
AgmatineThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Agmatine.
AlprazolamAlprazolam may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
Aluminum hydroxideThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Aluminum hydroxide.
AmilorideThe risk or severity of hyperkalemia can be increased when Potassium acetate is combined with Amiloride.
AmiodaroneThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Amiodarone.
AmitriptylinePotassium acetate may decrease the excretion rate of Amitriptyline which could result in a higher serum level.
AmlodipineThe risk or severity of hyperkalemia can be increased when Potassium acetate is combined with Amlodipine.
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C12554
ChemSpider
29104
ChEBI
32029
ChEMBL
CHEMBL1201058
Wikipedia
Potassium_acetate
ATC Codes
B05XA17 — Potassium acetate
AHFS Codes
  • 40:12.00 — Replacement Preparations

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, solutionIntravenous
Injection, solution, concentrateIntravenous
SolutionIntravenous
LiquidIntravenous
InjectionIntravenous
Injection, solutionIntravenous196 mg/1mL
Injection, solution, concentrateIntravenous196.3 mg/1mL
Injection, solution, concentrateIntravenous3.93 g/20mL
Injection, solution, concentrateIntravenous392 mg/1mL
SolutionIntravenous2 meq
LiquidIntravenous392 mg
SolutionIntravenous392 mg
LiquidIntravenous39.2 %
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility342.0 mg/mLALOGPS
logP-0.27ALOGPS
logP-0.22ChemAxon
logS0.54ALOGPS
pKa (Strongest Acidic)4.54ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area40.13 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity23.48 m3·mol-1ChemAxon
Polarizability4.96 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as acetate salts. These are organic compounds containing acetic acid as its acid component.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Carboxylic acid derivatives
Direct Parent
Acetate salts
Alternative Parents
Monocarboxylic acids and derivatives / Carboxylic acids / Organic potassium salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Acetate salt / Organic alkali metal salt / Monocarboxylic acid or derivatives / Carboxylic acid / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organic potassium salt / Organic salt / Organooxygen compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
potassium salt (CHEBI:32029)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid hormone binding
Specific Function
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
Gene Name
ATP1A1
Uniprot ID
P05023
Uniprot Name
Sodium/potassium-transporting ATPase subunit alpha-1
Molecular Weight
112895.01 Da
References
  1. Silva E, Gomes P, Soares-da-Silva P: Overexpression of Na(+)/K (+)-ATPase parallels the increase in sodium transport and potassium recycling in an in vitro model of proximal tubule cellular ageing. J Membr Biol. 2006;212(3):163-75. Epub 2007 Feb 28. [PubMed:17334838]
  2. Li C, Geering K, Horisberger JD: The third sodium binding site of Na,K-ATPase is functionally linked to acidic pH-activated inward current. J Membr Biol. 2006;213(1):1-9. Epub 2007 Mar 8. [PubMed:17347782]
  3. Stanely Mainzen Prince P, Karthick M: Preventive effect of rutin on lipids, lipoproteins, and ATPases in normal and isoproterenol-induced myocardial infarction in rats. J Biochem Mol Toxicol. 2007;21(1):1-6. [PubMed:17366541]
  4. Simon WA, Herrmann M, Klein T, Shin JM, Huber R, Senn-Bilfinger J, Postius S: Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther. 2007 Jun;321(3):866-74. Epub 2007 Mar 16. [PubMed:17369284]
  5. Iannello S, Milazzo P, Belfiore F: Animal and human tissue Na,K-ATPase in normal and insulin-resistant states: regulation, behaviour and interpretative hypothesis on NEFA effects. Obes Rev. 2007 May;8(3):231-51. [PubMed:17444965]

Drug created on July 11, 2018 10:28 / Updated on September 21, 2018 20:42